286. 遺伝性鉄芽球性貧血 Hereditary sideroblastic anemia Clinical trials / Disease details
臨床試験数 : 7 / 薬物数 : 23 - (DrugBank : 10) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 42
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000023490 | 2016/08/20 | 05/08/2016 | The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia | Sideroblastic anemia (congenital and acquired) | Food supplement containing 150 mg of ALA phosphate was given per day for 24 weeks. For the evaluation of efficacy and safety, medical examinations as well as urine and blood tests will be performed prior to administration of ALA, then at 2 and 4 weeks, and thereafter every month (up to 12 months). | Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 5 | Not applicable | Japan | |
| 2 | JPRN-UMIN000021407 | 2016/03/15 | 15/03/2016 | A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia | A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia | sideroblastic anemia | Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks. | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | SBI Pharmaceuticals Co., Ltd | Complete: follow-up continuing | 20years-old | 80years-old | Male and Female | 5 | Not applicable | Japan |